secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001193125-24-251014
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR
--------------------------------------------------------------------------------

- Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.
- iMMagine-1 (58 patients): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity at 10^-5.
- No delayed neurotoxicities (no parkinsonism, no cranial nerve palsies, no Guillain-Barré) observed across >140 patients dosed.
- First patient dosed in iMMagine-3 study (earlier lines); manufactured by Kite with turnaround time in line with Kite's commercial products.
- Data to be presented at ASH Annual Meeting Dec 7-10, 2024; company webcast Dec 9 at 8:30 p.m. PT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/0001193125-24-251014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312524251014/d844485d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-251014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer